Shares of United Therapeutics UTHR remained unaffected after the company reported Q3 results.
Quarterly Results
Earnings per share increased 1.31% over the past year to $3.88, which beat the estimate of $2.78.
Revenue of $380,100,000 decreased by 5.33% year over year, which beat the estimate of $356,950,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
United Therapeutics hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Oct 28, 2020
Time: 09:00 AM
ET Webcast URL: https://event.on24.com/wcc/r/2626227/98AF69ABC36C960CB46184532595C32D
Price Action
Company's 52-week high was at $127.79
52-week low: $75.58
Price action over last quarter: Up 8.72%
Company Overview
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for pulmonary arterial hypertension largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Nearly all of its sales are generated within the United States. United also markets a pediatric oncology drug, but its focus largely remains in pulmonary hypertension.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
